Open Access
| Issue |
BIO Web Conf.
Volume 111, 2024
2024 6th International Conference on Biotechnology and Biomedicine (ICBB 2024)
|
|
|---|---|---|
| Article Number | 01004 | |
| Number of page(s) | 4 | |
| Section | Genetic Engineering and Biotechnology Innovation | |
| DOI | https://doi.org/10.1051/bioconf/202411101004 | |
| Published online | 31 May 2024 | |
- Aubrey, B. J., et al. (2018). “How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?” Cell death & differentiation 25(1): 104-113. [CrossRef] [PubMed] [Google Scholar]
- Carvalho, C., et al. (2009). “Doxorubicin: the good, the bad and the ugly effect.” Current medicinal chemistry 16(25): 3267-3285. [CrossRef] [PubMed] [Google Scholar]
- Khan, F. M., et al. (2018). “Inhibition of exosome release by ketotifen enhances sensitivity of cancer cells to doxorubicin.” Cancer biology & therapy 19(1): 25-33. [CrossRef] [PubMed] [Google Scholar]
- Marei, H. E., et al. (2021). “P53 signaling in cancer progression and therapy.” Cancer cell international 21(1): 1-15. [CrossRef] [PubMed] [Google Scholar]
- Miyashita, T., et al. (1994). “Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.” Oncogene 9(6): 1799-1805. [PubMed] [Google Scholar]
- Peng, M., et al. (2017). “Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.” Cancer treatment reviews 54: 24-33. [CrossRef] [PubMed] [Google Scholar]
- Sritharan, S. and N. Sivalingam (2021). “A comprehensive review on time-tested anticancer drug doxorubicin.” Life sciences 278: 119527. [CrossRef] [PubMed] [Google Scholar]
- Thijssen, R., et al. (2021). “Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.” Blood, The Journal of the American Society of Hematology 137(20): 2721-2735. [Google Scholar]
- Torre, L. A., et al. (2016). “Global cancer incidence and mortality rates and trends—an update.” Cancer epidemiology, biomarkers & prevention 25(1): 16-27. [CrossRef] [PubMed] [Google Scholar]
- Yeh, P. Y., et al. (2004). “Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death.” Oncogene 23(20): 3580-3588. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.